Guerin 2002.

Methods	6‐Week wash‐out period 12‐Week single‐centre study Evening dose
Participants	11 men from France with type IIb hyperlipidaemia, mean age 51 years (35‐66); TC > 6.5 mmol/L (251 mg/dL), TG 1.71 to 4.57 mmol/L (151‐405) mg/dL Exclusion criteria: dysbetalipoproteinaemia, diabetes, secondary hypercholesterolaemia, uncontrolled HTN, major cardiovascular event, BMI > 30, alcohol abuse Baseline TC: 7.5 mmol/L (290 mg/dL) Baseline LDL‐C: 5.14 mmol/L (199 mg/dL) Baseline HDL‐C: 0.85 mmol/L (33 mg/dL) Baseline TG: 3.28 mmol/L (290.5 mg/dL)
Interventions	Atorvastatin 10 mg/d for 0 to 6 weeks Atorvastatin 40 mg/d for 6 to 12 weeks
Outcomes	Per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	First atorvastatin dose was analysed SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	High risk	Pfizer partially funded the study; data may support bias for atorvastatin